Navigation Links
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
Date:11/19/2009

ically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders.

Forward-Looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding the Company's ability to advance its clinical and preclinical pipeline, including completing its ongoing Phase 3 clinical trials of OMS103HP and funding the commercial launch of OMS103HP with the proceeds from its initial public offering; to realize the value of its GPCR program while limiting the Company's expenditures as a result of changes to its agreement with Patobios Limited; to release data from its Phase 3 arthroscopic program as well as meet additional clinical milestones for its ophthalmologic and urologic programs over the course of next year; and to de-orphanize orphan GPCRs and grant related development and/or commercialization rights to third parties. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors des
'/>"/>

SOURCE Omeros Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
11. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... University of Oregon chemist Geraldine Richmond, have tapped ... synthetic proteins called peptoid nanosheets that mimic complex ... detailed this week in a paper placed online ... the National Academy of Sciences -- is ... two-dimensional peptoid nanosheets that can be used in ...
(Date:9/2/2014)... , Sept. 2, 2014  TransCelerate BioPharma ... a recommended approach for protecting personal data in ... researchers, patients and others. The document describes an ... information from CSRs and other related clinical trial ... The goal of the TransCelerate CSR Redaction ...
(Date:9/2/2014)... 02, 2014 Opertech Bio, Inc., ... efficient, cost effective approach to sensory evaluation, today ... by the U.S. Patent and Trademark Office, encompassing ... , “Opertech’s taste evaluation technology called Microtiter ... high throughput system for rapid characterization of taste ...
(Date:9/2/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY ) announced ... Executive Officer, will present at the Rodman & Renshaw 16 ... York on Tuesday, Sept. 9, 2014 at 2:05 ... of the presentation will be accessible by visiting the Oncothyreon ... About Oncothyreon Oncothyreon is ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 2TransCelerate BioPharma Inc. Releases Recommended Approach for Protecting Personal Data in Clinical Study Reports 3Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2
... drug discovery and development services, cell lines, and reagents ... Feb. 26 The leading experts in ion channels ... discovery, development, and safety - are now united. ChanTest, ... validated cell lines, announced that it has acquired Rockville, ...
... the availability of Trade Alerts on stocks making news today. ... free by visiting: http://www.BeaconEquity.com/m Today,s Trade Alerts include: ... Industries Ltd. (Nasdaq: TEVA ), Allergan Inc. (NYSE: ... ), Vertex Pharmaceuticals Inc. (Nasdaq: VRTX ) and ...
... announced today that it has received U.S. Food and ... using the Biomerix Biomaterial(TM), REVIVE acts as a tissue ... in a variety of soft tissue repair procedures, including ... procedures per year, inguinal hernia repair is one of ...
Cached Biology Technology:ChanTest Acquires Applied Cell Sciences 2ChanTest Acquires Applied Cell Sciences 3ChanTest Acquires Applied Cell Sciences 4Beacon Equity Issues Technical Trade Alerts on Drug Manufacturer Stocks: FRX, TEVA, AGN, CEPH, VRTX, ADLR 2Biomerix Corporation Announces FDA Clearance and Market Launch of REVIVE(TM) for Use in Soft Tissue Repair Procedures 2
(Date:9/1/2014)... television making us fat? An increasing amount of research ... consumption and a more sedentary lifestyle. Now, a new ... is alike. Some TV programs might lead people to ... that if you,re watching an action movie while snacking ... Tal, Ph.D. lead author on the new article just ...
(Date:9/1/2014)... Conventional wisdom has long held that corals ... reefs are passive organisms that rely entirely ... as nutrients and oxygen. But now scientists at ... in Israel have found that they are far ... into turbulent patterns that greatly enhance their ability ...
(Date:9/1/2014)... basic building block of DNAcould initiate fragile X syndrome, the most ... The Journal of Cell Biology . , ... on the X chromosome called fragile X mental retardation 1 ... men carry a so-called premutation, in which a series of DNA ... slightly longer than normal. These repeats are prone to even further ...
Breaking Biology News(10 mins):Can action movies make you fat? 2Nature's tiny engineers 2Nature's tiny engineers 3A nucleotide change could initiate fragile X syndrome 2
... longest in the animal kingdom and they have largely ... scientists led by the University of Exeter have uncovered ... Africa and the results could have huge implications for ... the journal Current Biology, Dr Brendan Godley and an ...
... international team of scientists reported evidence, in a controversial cover ... more than 3.8 billion years ago--400 million years earlier than ... that team and two of the original authors will report ... , Craig E. Manning, lead author of the new study ...
... mouse is providing hope of a new treatment for ... transmission of serotonin in the brain. Serotonin is known ... sexuality. By breeding mice with an absence of TREK-1, ... of this research, which involved an international collaboration with ...
Cached Biology News:How satellite tracking revealed the migratory mysteries of endangered Atlantic loggerhead turtles 2UCLA scientists strengthen case for life more than 3.8 billion years ago 2UCLA scientists strengthen case for life more than 3.8 billion years ago 3UCLA scientists strengthen case for life more than 3.8 billion years ago 4UCLA scientists strengthen case for life more than 3.8 billion years ago 5Ever-happy mice may hold key to new treatment of depression 2
... Pig serum is collected from fasted Guinea Pigs. ... Citrate N-04: Heparin (Na) N-06: ... N-10: EDTA (Na) N-03: Alsevers ... N-09: K3EDTA N-11: Heparin ...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
EPH electrode, anode, 1. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
... precipitation offers major advantages over other RNA precipitation ... protein or carbohydrates. It is the method of ... synthesis from RNA preparations. Note, LiCl precipitation may ... isolations. If the RNA is to be used ...
Biology Products: